Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients

Current Medical Research and Opinion

Volumn 29, Issue 7, 2013, Pages 761-771

  Suh, Dong Churl ^a   Choi, Jiyoon C ^b   Schein, Jeff ^c   Kim, Suhyun ^a   Nelson, Winnie W ^c  

^a Chung Ang University   (South Korea)

^b LifeScan Inc   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Atrial flutter; Bleeding; Warfarin discontinuation

Indexed keywords

WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENDER; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; WARFARIN; YOUNG ADULT;

EID: 84880265764     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.795142     Document Type: Article

References (55)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA 2001;285:2370-75
2. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics, 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-6
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25
4. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk Ann Intern Med 1992;116:1-5
5. Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials: The Stroke Prevention in Atrial Fibrillation (SPAF) investigators. Stroke 1999;30:1223-9
6. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e531-75S
7. Fuster V, Rydén LE, Cannom DS, et al; Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation, executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27: 1979-2030
8. National Institute for Health and Clinical Excellence. The Management of Atrial Fibrillation (NICE Clinical Guideline 36). London: National Health Service, 2006
9. Algra A, Schryver ELD, Gijn JV, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006;3:CD001342
10. Mohr JP, Thompson JL, Lazar RM, et al; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51
11. Gullov A, Koefoed B, Peterson P. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation. Arch Intern Med 1998;158:1513-21
12. DiPiro JT, Talbert RL, Yee CC, et al. Pharmacotherapy: A Pathophysiologic Approach, 6th edn. New York, NY: McGraw-Hill, 2005
13. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 Suppl):8-21S
14. Ageno W, Gallus AS, Wittkowsky A, et al; American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44-88S
15. Fanikos J, Stapinski C, Koo S, et al. Medication errors associated with anti-coagulant therapy in the hospital. Am J Cardiol 2004;94:532-5
16. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient preference and adherence. Patient Prefer Adherence 2010;4: 51-60
17. HylekEM, Evans-Molina C, SheaC, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96
18. De Schryver E, Van Gijn J, Kapelle L, et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005;252:1316-21
19. US Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate) [package insert]. Boehringer Ingelheim Pharmaceuticals Inc. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022512s007lbl.pdf [Last accessed 14 February 2013]
20. US Food and Drug Administration. Xarelto (rivaroxaban) [package insert] Janssen Pharmaceuticals Inc. 2011. Available at: http://www.accessdata.f-da.gov/ drugsatfda-docs/label/2011/202439s001lbl.pdf [Last accessed 14 February 2013]
21. US Food and Drug Administration. Eliquis (apixaban) [package insert]. Bristol-Myers Squibb Company. 2012. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/202155s000lbl.pdf [Last accessed 14 February 2013]
22. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
23. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011;57:1330-7
24. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011;62:41-57
25. Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 2012;125: 159-64
26. Ahmad Y, Lip GY. Stroke prevention in atrial fibrillation: where are we now? Clin Med Insights Cardiol 2012;6:65-78
27. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
28. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 2011;365:883-91
29. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
30. Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 2013;35:391-8
31. Lindh J, Holm L, Dahl M. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008;25:151-9
32. Adamson DM, Chang S, Hansen LG. Health Research Data for the Real World: The MarketScan Databases (white paper). Ann Arbor, MI: Thomson Reuters, 2008
33. Boulanger L, Hauch O, Friedman M, et al. Warfarin exposure and the risk of thromboembolic and major bleeding events among Medicaid patients with atrial fibrillation. Ann Pharmacother 2006;40:1024-9
34. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-92
35. Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005;94: 537-43
36. Douketis JD, Melo M, Bell CM, Mamdani MM. Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin? Am J Med 2007;120:369 e9-369.e314
37. American Society of Health-System Pharmacists. American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 2009
38. Arnason T, Wells PS, Walraven CV, Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 2006;118:253-62
39. Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm 2006;12:640-8
40. Hansten PD, Horn JR, eds. Hansten and Horn's Drug Interactions Analysis and Management. St. Louis, MO: Facts and Comparisons, 2009
41. Coumadin (warfarin sodium) [package insert]. Bristol-Myers Squibb Company. 2011. Available at: http://packageinserts.bms.com/pi/pi-couma-din.pdf [Last accessed 14 March 2013]
42. Tatro DS. Drug Interaction Facts. St. Louis, MO: Wolters Kluwer Health, 2010
43. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
44. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: John Wiley & Sons, 1999
45. Lee ET. Statistical Methods for Survival Data Analysis. New York, NY: Wiley-Interscience Publications, 1992
46. Agresti A. Categorical Data Analysis, 2nd edn. New York, NY: John Wiley & Sons, 2002
47. Wing S, Richardson D, Wolf S, et al. A case control study of multiple myeloma at four nuclear facilities. Ann Epidemiol 2000;10:144-53
48. Gallagher A, Rietbrock S, Plumb J, Van Staa T. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis. J Thromb Haemost 2008;6:1500-6
49. Srivastava A, Hudson M, Hamoud I, et al. Examining warfarin underutilization rates in patients with atrial fibrillation: detailed chart review essential to capture contraindications to warfarin therapy. Thromb J 2008;6:1-6
50. Hylek E, Go AS, Chang Y. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26
51. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006;130:1390-6
52. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007;100: 599-607
53. Targownik L, Metge C, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of non-steroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-44
54. Battistella M, Mamdami MM, Juurlink DN, et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005;165:189-92
55. Cattaruzzi C, Troncon MG, Agostinis L, Rodriguez LAG. Positive predictive value of ICD-9 codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale Database. J Clin Epidemiol 1999;52:499-502